GlassScriptPhysician profile
Diane Speelman
NPI 1952637241
$6,850.29
in general payments reported to CMS, 2019-2025
19 companies · $5,500 in 2025
The $5,500 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $135 · 2024: $1,215 · 2025: $5,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491 · Travel and Lodging: $1,647 · Honoraria: $600 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,490.78 |
| Travel and Lodging | $1,647.14 |
| Honoraria | $600.00 |
| Education | $112.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $2,416.63 | 2025 | Monoferric, Cosela |
| Janssen Biotech, INC. | $671.59 | 2024-2025 | Carvykti, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals LP | $602.34 | 2024-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $468.48 | 2023-2025 | Opdivo, Reblozyl |
| Gilead Sciences, INC. | $434.94 | 2025 | |
| Astellas Pharma Global Development | $281.26 | 2025 | Padcev, Xtandi |
| Daiichi Sankyo INC. | $273.63 | 2024-2025 | Injectafer |
| Abbvie INC. | $224.88 | 2025 | |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Genentech USA, INC. | $147.54 | 2024 | Columvi, Lunsumio |
| Novartis Pharmaceuticals Corporation | $145.92 | 2025 | |
| American Regent | $144.86 | 2025 | Injectafer |
| Caris Mpi, INC. | $136.53 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $127.95 | 2025 | |
| Adc Therapeutics America, INC. | $127.01 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.00 | 2024 | |
| Incyte Corporation | $124.99 | 2025 | Zynyz |
| Sobi, INC | $124.94 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.80 | 2025 | Fruzaqla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Speelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.